Background: Targeted therapy options in HER2-negative breast cancer are limited. This open-label, multicenter phase IB dose-escalation trial was conducted to determine safety, tolerability, and antitumor activity of a combination of docetaxel (Taxotere) and increasing doses of adecatumumab, a human IgG1 antibody targeting epithelial cell adhesion molecule (EpCAM), in EpCAM-positive relapsed or primary refractory advanced-stage breast cancer.
introduction
Although mortality rates in patients with breast cancer are decreasing across the United States and the European Union [1] , prognosis in patients with advanced breast cancer remains poor. While patients with HER2-positive tumors benefit from trastuzumab and lapatinib, only 25% of women belong to this group [2] . Treatment options in patients with HER2-negative or estrogen-independent advanced breast cancer are limited. Clearly, there is a need to develop targeted therapies for those 75% of patients with HER2-negative tumors and those that do not respond to anti-hormonal therapies.
The epithelial cell adhesion molecule (EpCAM) is expressed by a majority of human tumors making it an attractive diagnostic and therapeutic target in oncology. Overexpression of EpCAM appears to promote proliferation, migration, and invasiveness of breast cancer cells [3, 4] . EpCAM protein expression is detected in >90% of breast cancers, and high expression levels were associated with inferior outcome in several retrospective analyses [5] [6] [7] . EpCAM RNA expression was confirmed as an independent prognostic parameter in three cohorts of medically untreated node-negative breast cancer patients [8] . Against this background, adecatumumab (MT201), a fully human monoclonal IgG1 antibody binding EpCAM with moderate affinity, was developed for cancer treatment [9] . Adecatumumab monotherapy delayed disease progression in phase II studies in advanced breast cancer and hormone-refractory prostate cancer [10, 11] ; additional trials are ongoing in colorectal cancer. As a human antibody with only moderate affinity for EpCAM, adecatumumab may circumvent organ toxic effects observed in earlier trials with high-affinity humanized anti-EpCAM antibodies [12, 13] . Adecatumumab monotherapy was generally well tolerated in phase I and II studies, showing mainly dose-dependent moderate gastrointestinal toxic effects [10, 11, 14] .
Clinically approved monoclonal antibodies, such as trastuzumab, cetuximab, or bevacizumab, have been shown to enhance the clinical activity of simultaneously administered cytotoxic chemotherapy or radiation. This contrasts with the usually low-to-moderate clinical activity of antibody monotherapy in solid cancers. The present phase IB study was conducted to determine the safety and tolerability of a standard regimen of docetaxel (100 mg/m 2 every 3 weeks) in combination with increasing doses of adecatumumab in heavily pretreated patients with EpCAM-positive relapsed or primary refractory advanced-stage breast cancer.
methods study design
The study was an open-label, multicenter phase IB dose-escalation trial investigating the safety and tolerability of a combined regimen of adecatumumab and docetaxel (Taxotere, Sanofi-aventis) in patients with EpCAM-positive relapsed or primary refractory advanced-stage breast cancer (EudraCT number: 2004-004560-79). The primary end point was the overall frequency of adverse events (AEs), including clinical symptoms, laboratory abnormalities, serious adverse events (SAEs), and treatmentlimiting AEs. Secondary end points included pharmacokinetics of adecatumumab and docetaxel, pharmacodynamic parameters, and clinical response rates according to RECIST [15] .
The study protocol was approved by the responsible German and Austrian ethics committees and conducted according to the recommendations of the Declaration of Helsinki, as amended in Somerset West, South Africa (1996) and Edinburgh, Scotland (2000), the respective local drug law, and ICH-GCP [16] . All patients provided signed informed consent.
study population
Women (aged ≥ 18 years) with relapsed or primary refractory advancedstage breast cancer (Eastern Cooperative Oncology Group performance status of ≤2; life expectancy ≥ 6 months) had to have immunohistochemically confirmed EpCAM expression on the most recent available tumor specimen and at least one measurable tumor lesion according to RECIST. Patients were categorized as having low-or highlevel EpCAM expression on the basis of immunohistochemical testing [5] . Patients could have received up to four previous chemotherapy regimens for advanced breast cancer.
Exclusion criteria included patients with clinically symptomatic or progressive brain metastases; cancer chemotherapy within 4 weeks or treatment with any investigational product within 12 weeks before study entry; abnormal organ or bone marrow function; history of malignancy other than breast cancer within 5 years of study start (exceptions being basal cell carcinoma of the skin and carcinoma in situ of the cervix); active severe infection or any other concurrent disease or medical condition judged by the investigator to interfere with the conduct of the study; use of immunosuppressive agents (e.g. the regular use of systemic corticosteroids) for 4 weeks before study start; known hypersensitivity to any component of the study drug formulation; and pregnant or nursing women or women of childbearing potential not willing to use an effective form of contraception during and for at least 3 months after the study.
treatment schedule
Following a 3-week screening period, patients were alternately assigned to either a three-weekly (q3w) or a weekly (qw) schedule of increasing doses of adecatumumab for 15 (q3w schedule) or 17 weeks (qw schedule) (Figure 1) . Patients who derived clinical benefit were eligible for two additional administrations of docetaxel combined with either two (q3w schedule) or six (qw schedule) doses of adecatumumab. Patients were followed for 7 weeks after treatment.
Dose-escalation of adecatumumab followed a typical 3 + 3 dose-limiting toxicity (DLT) design. The next dose level was opened when three patients completed at least two administrations of docetaxel and 3 (q3w) and 4 (qw), respectively, administrations of adecatumumab without the occurrence of a DLT. The DLT period was 29 days, starting from first administration of adecatumumab/docetaxel. A Data Review Committee (DRC) evaluated the safety data before opening the next dose level. Patients who completed fewer than two administrations of docetaxel were replaced (unless the reason was DLT related). Patients progressing under therapy were discontinued.
In the q3w dosing schedule, adecatumumab loading doses of 100, 300, or 550 mg/m 2 on days 0 and 7 were to be followed by respective maintenance doses of 180, 550, or 1000 mg/m 2 on day 21. The maintenance dose was then repeated every 21 days. In the qw dosing schedule, adecatumumab was to be infused at doses of 180, 360, 550, and 1000 mg/m 2 , starting on day 0 and repeated weekly. In both dosing schedules, docetaxel 100 mg/m 2 was administered every 21 days 1 h after the end of the adecatumumab infusion. Treatment was continued until the occurrence of a DLT, intolerable toxicity, or disease progression. A DLT was defined as an NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grade 3/4 AEs; a laboratory abnormality occurring during the DLT period and considered at least possibly related to the investigational drug; clinically evident pancreatitis (CTCAE of grade 2 or more); or a toxicity delaying treatment by ≥14 days.
No concomitant antitumor therapy, high-dose corticosteroids, or other immunosuppressive agents were to be administered. Dexamethasone was allowed to mitigate infusion-related symptoms and was administered as recommended for docetaxel therapy. Supportive therapy of other adecatumumab-/docetaxel-induced toxic effects was permitted. If neutropenia threatened to delay treatment, the administration of granulocyte-colony stimulating factors was recommended.
assessment of safety and tolerability
Safety evaluations involved physical examinations, laboratory parameters, measurement of vital signs, and recording of toxic effects according to CTCAE version 3.0. Cardiac function was assessed by echocardiography. Adecatumumab immunogenicity was assessed using human anti-human antibodies at screening, during treatment (day 105), and at the end-ofstudy visit.
Patients were followed up until the end-of-study visit or up to 30 days after the end of treatment of the occurrence of AEs; they were monitored until the AE resolved, the condition stabilized, or its cause was identified completely. 
pharmacodynamics/pharmacokinetics
Serum concentrations of tumor necrosis factor (TNF)-α, interferon-γ, interleukin (IL)-2 and IL-12 were assessed using enzyme-linked immunosorbent assays and cytometric bead array techniques. Serum concentrations of adecatumumab and docetaxel were measured in all patients using validated assays. Blood samples were taken before each drug infusion to determine trough levels and following the end of infusion to assess peak levels.
efficacy evaluations
Response to treatment was evaluated every 6 weeks by computed tomography scanning according to RECIST. In addition, the clinical benefit rate, defined as the percentage of patients experiencing a confirmed complete response or partial response (PR) or stable disease for ≥ 6 months, was determined.
statistical analysis
All parameters were analyzed using descriptive methods and no confirmatory testing was carried out. Safety was analyzed using the full analysis set (FAS) of all patients who received at least one infusion of adecatumumab. Efficacy was analyzed using the per-protocol analysis set of all FAS patients who did not deviate from the protocol. Time to progression (TTP), defined as the time from the start of adecatumumab treatment to the recorded time of disease progression or death, was analyzed using Kaplan-Meier methodology.
results
Five centers in Germany and two in Austria screened 51 patients, 31 of whom were enrolled into the study. Reasons for screening failure included EpCAM-negativity, withdrawal of consent, and worsening of a concurrent medical condition. All patients were Caucasian, had stage IV disease at enrollment, and had been heavily pretreated (mean of five previous chemoor hormonal therapies) ( Table 1) . Fourteen of 22 patients in the q3w group and all patients in the qw group had received prior radiotherapy.
Seventeen patients discontinued prematurely because of AEs (supplemental Figure S1 , available at Annals of Oncology online): thrombocytopenia and leukocytopenia (one patient), diarrhea (two patients), and decline in performance status (one patient) in the q3w group and sepsis (two patients), multiorgan failure and diarrhea (one patient each) in the qw group.
drug exposure
Patients assigned to q3w or qw dosing received 5.9 ± 3.0 or 9.6 ± 5.0 (mean ± standard deviation) adecatumumab cycles, respectively. For both dosing schedules, patients at dose level 1 received slightly fewer cycles than patients at dose level 2 (q3w: 5.1 ± 3.1 versus 6.2 ± 3.1 cycles; qw: 7.7 ± 3.1 versus 10.5 ± 5.8 cycles). The corresponding numbers of docetaxel doses were 4.9 ± 3.0 and 4.1 ± 2.3, respectively. Again, patients at dose level 1 received slightly fewer cycles than patients at dose level 2 (4.1 ± 3.1 versus 5.2 ± 3.1 and 3.0 ± 1.0 versus 4.7 ± 2.7, respectively).
safety
Most AEs reported in this study were of mild to moderate severity. The most frequently reported grade 3/4 AEs in both dosing groups included neutropenia, leukocytopenia and lymphopenia, and diarrhea (Table 2 ). For the q3w and qw schedules, 82% and 72% of AEs, respectively, were considered treatment related. Seventy-five percent and 80% of both overall AEs and drug-related AEs reported during q3w and qw dosing, respectively, occurred at dose level 2.
Higher proportions of SAEs due to leukocytopenia, neutropenia, and lymphopenia were considered related to docetaxel rather than to adecatumumab administration (supplemental Table S1 , available at Annals of Oncology online).
Only three patients experienced elevated liver enzymes (transaminases and/or gamma-glutamyltransferase) and pancreatic (amylase and/or lipase) enzymes of grade 3 or more. Diarrhea of grade 3 or more was observed in four (18%) and three (33%) patients in the q3w and qw groups, respectively (Table 2) .
Three patients experienced diarrhea as a DLT. All DLTs occurred at dose level 2 in the q3w schedule. No DLTs were observed with the qw group. Based on an overall assessment of the AE profile, the DRC determined the maximum tolerated dose of adecatumumab given in combination with docetaxel (100 mg/m 2 q3w) to be 550 mg/m 2 for the q3w schedule and 360 mg/m 2 for the qw schedule. Two patients receiving q3w dosing and three patients receiving qw dosing died during the study; all had been treated at dose level 2. The two SAEs leading to death in the q3w group were tumor progression and sepsis; neither was considered related to study treatment. In the qw group, two cases of fatal sepsis were considered possibly or probably related to docetaxel. One case of multi-organ failure was not considered drug related. In addition, one patient treated at dose level 1 (q3w) who discontinued treatment prematurely due to a significant AE (decline in performance status) died of tumor progression on day 48. This death was considered possibly related to study treatment.
Electrocardiogram analysis revealed no cardiac events associated with adecatumumab treatment when given in combination with a standard dose of docetaxel.
pharmacokinetics/pharmacodynamics
Adecatumumab serum concentrations were dose-proportional for dose levels 1 and 2. Concentrations were comparable for all patients within each dose level (dose levels 1 and 2) and dosing schedule (q3w and qw). In general, adecatumumab concentrations in the qw group were higher than those in the q3w group. However, drug exposure was higher in the q3w group. Docetaxel levels for all patients were comparable within each dosing regimen (q3w and qw). No effect of adecatumumab on plasma levels of co-administered docetaxel could be demonstrated, as inter-dosing group variances in docetaxel plasma concentrations were high. Neither dosing schedule nor dose level had any marked effect on serum cytokine levels. One patient receiving qw dosing at dose level 2 showed a significant elevation in TNF-α levels shortly after the end of adecatumumab infusion on day 7.
No signs of immunogenicity against adecatumumab could be detected with either dosing regimen.
response to therapy
Response to therapy was evaluable in 27 patients (Table 3) . Within the q3w dose group, 22% of patients experienced a confirmed PR and the clinical benefit rate was 44%. Both the PR rate and clinical benefit rate were 11% in the qw dosing group. Although stable disease was achieved in 33% of patients, it did not last for at least 6 months. The most sustained antitumor activity of the q3w dosing schedule was achieved in patients with high EpCAM levels and in patients treated at dose level 2 (Table 3 ). Due to the low patient numbers and response rate in the qw group, no correlation between EpCAM expression and clinical benefit could be determined.
Median TTP was longer in q3w patients than in qw patients (5.5 months versus 2.7 months), in the subgroup of q3w patients with high EpCAM-expressing tumors than in those with low EpCAM-expressing tumors (5.5 months versus 4.8 months) and in those treated at dose level 2 versus dose level 1 (median TTP 5.7 months versus 2.7 months).
discussion
Adecatumumab is a promising new monoclonal antibody for the treatment of EpCAM-positive breast cancers. Here, we have determined the safety and tolerability of adecatumumab when combined with standard-dose docetaxel in heavily pretreated breast cancer patients. The toxicity profile observed with adecatumumab plus docetaxel clearly resembled that associated with single-agent docetaxel [17] and, to a much lesser extent, that of adecatumumab monotherapy. The most commonly reported AEs with a standard regimen of docetaxel monotherapy in pretreated patients with metastatic breast 
AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities. cancer are neutropenia, neutropenic fever, leukocytopenia, fluid retention, stomatitis, diarrhea, and alopecia [18] [19] [20] [21] . In contrast, AEs reported in a phase II trial of adecatumumab monotherapy in a similar population included chills, fatigue, headache, and gastrointestinal AEs, such as diarrhea [10] . It should be noted, however, that the use of a lower dose of docetaxel (75 mg/m 2 q3w), as is common in clinical practice in heavily pretreated patients [22] , may have resulted in fewer toxic effects than a standard dose of docetaxel. Because the incidence and severity of AEs were higher at dose level 2 in both dosing schedules, it is possible that adecatumumab contributed in a dose-dependent manner to the incidence and severity of certain AEs caused by docetaxel. Dose-dependent toxicity has previously been observed with adecatumumab in phase I and II studies [10, 11, 14] . Because of different patient numbers at each dose level and differences in docetaxel exposure between dose levels, it is difficult to accurately assess the contribution of adecatumumab to the AEs known for docetaxel.
Pharmacokinetic/pharmacodynamic analyses verified that combination therapy with adecatumumab and docetaxel was safe and feasible. No effect of adecatumumab on plasma levels of co-administered docetaxel could be demonstrated. In addition, no significant release of systemic cytokines by adecatumumab and docetaxel was observed, and the low immunogenicity of adecatumumab, as seen in a previous study [10] , was maintained in combination with docetaxel.
One patient showed a significant elevation in TNF-α shortly after the end of adecatumumab infusion. Similar dosedependent increases in TNF-α serum levels were observed in the first phase I study with single-agent adecatumumab in patients with hormone-refractory prostate cancer [14] . Further studies are needed to determine appropriate pharmacodynamic markers for the activation of immune effector cells by adecatumumab.
In the present study, adecatumumab and docetaxel combination therapy was mostly administered as third-or fourth-line treatment. Nevertheless, patients receiving q3w dosing experienced a PR rate according to RECIST of 22% and a clinical benefit rate of 44%. These response rates compare favorably with those reported in the few published studies of standard docetaxel monotherapy as third-and fourth-line therapy in patients previously treated with taxanes [18] [19] [20] [21] .
Previous findings of greater efficacy of adecatumumab in patients with high EpCAM-expressing tumors and at higher doses [10, 11] were supported by the results of the current study: 37% of patients receiving q3w adecatumumab with high EpCAM-expressing tumors showed an objective response and 63% experienced a clinical benefit. Comparable percentages in patients with low EpCAM-expressing tumors were 10% and 30%. Median TTP was also longer (although not statistically significantly) in the subgroup of patients with high EpCAMexpressing tumors (5.5 months; q3w) when compared with those with low levels of EpCAM expression (4.8 months; q3w). Overall, the median TTP observed in the present study is consistent with the 4.6 months reported by Wheler et al. [23] in 92 heavily pretreated patients (median of five prior therapies) with metastatic breast cancer who had undergone investigational treatment in a phase I trial. In this small population of heavily pretreated patients with relapsed or primary refractory advanced-stage breast cancer, the toxicity profile of adecatumumab in combination with docetaxel was manageable and comparable to that described for docetaxel monotherapy. As observed for other targeted agents, adecatumumab at higher doses may have increased the incidence and severity of docetaxel-induced toxic effects. The objective response rates observed in this heavily pretreated patient population are suggestive for clinical activity of adecatumumab in combination with docetaxel. Notably, patients with high intratumoral EpCAM expression appeared to benefit the most from chemoimmunotherapy. As EpCAM is highly expressed in ∼50% of breast cancers [5] , adecatumumab added to taxane-based chemotherapy has the potential to provide a novel treatment option to a substantial proportion of patients with metastatic breast cancer. Given the fact that EpCAM also is a negative prognostic marker in metastatic and locally advanced breast cancer patients, future prospective studies should clarify whether EpCAM expression can also be used as a predictor for clinical benefit from adecatumumab. 
